Literature DB >> 26057496

The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.

Dino Veneri1, Lorenza Soligo1, Giovanni Pizzolo1, Achille Ambrosetti1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26057496      PMCID: PMC4624556          DOI: 10.2450/2015.0325-14

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  4 in total

Review 1.  Thrombopoietin-receptor agonists for primary immune thrombocytopenia.

Authors:  Paul Imbach; Mark Crowther
Journal:  N Engl J Med       Date:  2011-08-25       Impact factor: 91.245

2.  B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

Authors:  Francesco Zaja; Isabella Iacona; Paola Masolini; Domenico Russo; Alessandra Sperotto; Simonetta Prosdocimo; Francesca Patriarca; Salvatore de Vita; Mario Regazzi; Michele Baccarani; Renato Fanin
Journal:  Haematologica       Date:  2002-02       Impact factor: 9.941

3.  The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.

Authors:  Matthieu Mahévas; Olivier Fain; Mikael Ebbo; Françoise Roudot-Thoraval; Nicolas Limal; Mehdi Khellaf; Nicolas Schleinitz; Philippe Bierling; Laeticia Languille; Bertrand Godeau; Marc Michel
Journal:  Br J Haematol       Date:  2014-04-12       Impact factor: 6.998

Review 4.  Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.

Authors:  Diane Nugent; Robert McMillan; Janet L Nichol; Sherrill J Slichter
Journal:  Br J Haematol       Date:  2009-05-14       Impact factor: 6.998

  4 in total
  1 in total

1.  A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies.

Authors:  Hanyin Wang; Hande Tuncer
Journal:  Case Rep Hematol       Date:  2018-07-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.